CH585793A5
(da)
|
1974-02-01 |
1977-03-15 |
Nestle Sa |
|
JPS5322158B2
(da)
|
1974-05-02 |
1978-07-06 |
|
|
US4237224A
(en)
|
1974-11-04 |
1980-12-02 |
Board Of Trustees Of The Leland Stanford Jr. University |
Process for producing biologically functional molecular chimeras
|
IT1130242B
(it)
|
1980-02-01 |
1986-06-11 |
Anic Spa |
Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
US5059421A
(en)
|
1985-07-26 |
1991-10-22 |
The Liposome Company, Inc. |
Preparation of targeted liposome systems of a defined size distribution
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
WO1990011353A1
(en)
|
1989-03-24 |
1990-10-04 |
Research Corporation Technologies, Inc. |
Recombinant alpha-galactosidase, a therapy for fabry disease
|
DE69033710T2
(de)
|
1989-10-24 |
2001-06-13 |
Chiron Corp |
Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
|
US5382524A
(en)
|
1990-10-24 |
1995-01-17 |
The Mount Sinai School Of Medicine Of The City University Of New York |
Cloning and expression of biologically active α-n-acetylgalactosaminidase
|
US5401650A
(en)
|
1990-10-24 |
1995-03-28 |
The Mount Sinai School Of Medicine Of The City University Of New York |
Cloning and expression of biologically active α-galactosidase A
|
US5773278A
(en)
|
1991-05-03 |
1998-06-30 |
Mount Sinai Medical Center |
Acid sphingomyelinase gene
|
FR2681786A1
(fr)
|
1991-09-27 |
1993-04-02 |
Centre Nat Rech Scient |
Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
|
IL103059A0
(en)
|
1991-09-30 |
1993-02-21 |
Boehringer Ingelheim Int |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
NZ244306A
(en)
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5433946A
(en)
|
1991-10-11 |
1995-07-18 |
Health Research Inc. |
Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
|
GB9223084D0
(en)
|
1992-11-04 |
1992-12-16 |
Imp Cancer Res Tech |
Compounds to target cells
|
US5631237A
(en)
|
1992-12-22 |
1997-05-20 |
Dzau; Victor J. |
Method for producing in vivo delivery of therapeutic agents via liposomes
|
AU5950694A
(en)
|
1992-12-30 |
1994-08-15 |
George Joe Revis |
Anticaries compositions
|
US5681811A
(en)
|
1993-05-10 |
1997-10-28 |
Protein Delivery, Inc. |
Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
|
CA2163860A1
(en)
|
1993-06-30 |
1995-01-12 |
Chung C. Hsu |
Method for preparing liposomes
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
US6294202B1
(en)
|
1994-10-06 |
2001-09-25 |
Genzyme Corporation |
Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
|
CA2203809C
(en)
|
1994-10-28 |
2008-06-03 |
James M. Wilson |
Recombinant adenovirus and methods of use thereof
|
US5997861A
(en)
|
1994-10-31 |
1999-12-07 |
Burstein Laboratories, Inc. |
Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
|
US5817789A
(en)
|
1995-06-06 |
1998-10-06 |
Transkaryotic Therapies, Inc. |
Chimeric proteins for use in transport of a selected substance into cells
|
US5643599A
(en)
|
1995-06-07 |
1997-07-01 |
President And Fellows Of Harvard College |
Intracellular delivery of macromolecules
|
US5994128A
(en)
|
1995-06-15 |
1999-11-30 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6118045A
(en)
|
1995-08-02 |
2000-09-12 |
Pharming B.V. |
Lysosomal proteins produced in the milk of transgenic animals
|
AU726544B2
(en)
|
1995-12-08 |
2000-11-09 |
University Of Alabama At Birmingham Research Foundation, The |
Targeted adenovirus vectors
|
US5994132A
(en)
|
1996-10-23 |
1999-11-30 |
University Of Michigan |
Adenovirus vectors
|
US6884435B1
(en)
|
1997-01-30 |
2005-04-26 |
Chiron Corporation |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
ES2268799T3
(es)
|
1997-10-29 |
2007-03-16 |
Genzyme Corporation |
Terapia genica para la enfermedad de gaucher.
|
WO1999045960A1
(en)
|
1998-03-10 |
1999-09-16 |
The Trustees Of The University Of Pennsylvania |
Enhancement of intracellular delivery and tissue targeting of drugs and genes
|
US5981225A
(en)
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
US6274597B1
(en)
|
1998-06-01 |
2001-08-14 |
Mount Sinai School Of Medicine Of New York University |
Method of enhancing lysosomal α-Galactosidase A
|
US7018628B1
(en)
|
1998-07-24 |
2006-03-28 |
Aventis Pharma S.A. |
Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
|
US6258581B1
(en)
|
1998-08-20 |
2001-07-10 |
Takara Shuzo Co., Ltd. |
Ceramidase gene
|
JP4854114B2
(ja)
|
1998-09-11 |
2012-01-18 |
シュミドマイヤー,ゲルハルド |
生物学的に活性なインプラント
|
US6790657B1
(en)
|
1999-01-07 |
2004-09-14 |
The United States Of America As Represented By The Department Of Health And Human Services |
Lentivirus vector system
|
GB9909064D0
(en)
|
1999-04-20 |
1999-06-16 |
Oxford Glycosciences Uk Ltd |
Therapies
|
US6730297B1
(en)
|
1999-05-28 |
2004-05-04 |
Chiron Corporation |
Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
|
US7927587B2
(en)
|
1999-08-05 |
2011-04-19 |
Regents Of The University Of Minnesota |
MAPC administration for the treatment of lysosomal storage disorders
|
US6767741B1
(en)
|
1999-08-27 |
2004-07-27 |
Invitrogen Corporation |
Metal binding compounds and their use in cell culture medium compositions
|
US6537785B1
(en)
|
1999-09-14 |
2003-03-25 |
Genzyme Glycobiology Research Institute, Inc. |
Methods of treating lysosomal storage diseases
|
IL149093A0
(en)
|
1999-10-13 |
2002-11-10 |
Yeda Res & Dev |
Short segments of dap-kinase
|
US6350768B1
(en)
|
1999-11-24 |
2002-02-26 |
Aventis Pharma S.A. |
Combination of riluzole and of gabapentin and its use as a medicament
|
US7850984B2
(en)
|
2000-02-15 |
2010-12-14 |
The General Hospital Corporation |
Protection of the female reproductive system from natural and artificial insults
|
AU2001253181A1
(en)
|
2000-04-06 |
2001-10-23 |
Exegenics, Inc. |
Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
|
US20040204379A1
(en)
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
ES2523856T3
(es)
|
2000-12-22 |
2014-12-02 |
Lpath, Inc. |
Anticuerpos de esfingosina-1-fosfato para el tratamiento de enfermedades asociadas con elevadas concentraciones de esfingolípidos
|
US20020142299A1
(en)
|
2001-01-09 |
2002-10-03 |
Davidson Beverly L. |
PTD-modified proteins
|
EP1234816B1
(de)
|
2001-02-23 |
2004-06-30 |
Biofrontera Pharmaceuticals GmbH |
Scyphostatin-Analoga als SMase-Inhibitoren
|
ATE384736T1
(de)
|
2001-04-30 |
2008-02-15 |
Zystor Therapeutics Inc |
Subzelluläres targeting von therapeutischen proteinen
|
US7232670B2
(en)
|
2001-09-28 |
2007-06-19 |
St. Jude Children's Research Hospital |
Targeting proteins to cells expressing mannose receptors via expression in insect cells
|
EP1463800A4
(en)
|
2001-12-07 |
2006-04-26 |
Geron Corp |
CHONDROCYTE PRE-CREATOR CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS
|
US7169610B2
(en)
|
2002-01-25 |
2007-01-30 |
Genzyme Corporation |
Serum-free media for chondrocytes and methods of use thereof
|
US20050107868A1
(en)
|
2002-03-28 |
2005-05-19 |
JAPAN as represented by President of NATIONAL & CARDIOVASCULAR CENTER |
Scaffold for tissue engineering, artificial blood vessel, cuff, and biological implant covering member
|
US7658916B2
(en)
|
2002-04-05 |
2010-02-09 |
Genzyme Corporation |
Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
|
DE10239531A1
(de)
|
2002-08-23 |
2004-03-04 |
Gulbins, Erich, Prof. Dr. |
Prophylaxe und Therapie von Infektionserkrankungen
|
US7220578B2
(en)
|
2002-11-27 |
2007-05-22 |
Tal Kafri |
Single LTR lentivirus vector
|
EP1431399A1
(en)
|
2002-12-20 |
2004-06-23 |
Clinigenetics |
Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
|
US20040126405A1
(en)
|
2002-12-30 |
2004-07-01 |
Scimed Life Systems, Inc. |
Engineered scaffolds for promoting growth of cells
|
ES2371913T3
(es)
|
2003-01-22 |
2012-01-11 |
Duke University |
Constructos mejorados para expresar polipéptidos lisosomales.
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
CA2895272A1
(en)
|
2003-07-17 |
2005-02-03 |
Pacific Edge Biotechnology, Ltd. |
Markers for detection of gastric cancer
|
US7897384B2
(en)
|
2003-09-08 |
2011-03-01 |
Ethicon, Inc. |
Chondrocyte therapeutic delivery system
|
US7919094B2
(en)
*
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US8889127B2
(en)
|
2004-07-01 |
2014-11-18 |
Icahn School Of Medicine At Mount Sinai |
Targeted protein replacement for the treatment of lysosomal storage disorders
|
US8017394B2
(en)
|
2004-10-01 |
2011-09-13 |
Isto Technologies, Inc. |
Method for chondrocyte expansion with phenotype retention
|
US7273756B2
(en)
|
2004-10-01 |
2007-09-25 |
Isto Technologies, Inc. |
Method for chondrocyte expansion with phenotype retention
|
WO2006050265A2
(en)
|
2004-10-29 |
2006-05-11 |
Musc Foundation For Research Development |
Ceramides and apoptosis-signaling ligand
|
US7993868B2
(en)
|
2005-04-19 |
2011-08-09 |
Vermillion, Inc. |
Saposin D and FAM3C are biomarkers for alzheimer's disease
|
US20070162992A1
(en)
|
2006-01-09 |
2007-07-12 |
Mcgill University |
Metabolomic determination in assisted reproductive technology
|
CA2640614A1
(en)
|
2006-01-27 |
2007-08-09 |
Eastern Virginia Medical School |
Proteomic fingerprinting of human ivf-derived embryos: identification of biomarkers of developmental potential
|
WO2007095688A1
(en)
|
2006-02-23 |
2007-08-30 |
The Australian National University |
Methods for increasing the number of circulating cells
|
CA2650311A1
(en)
|
2006-04-24 |
2007-11-01 |
Academisch Medisch Centrum |
Improved treatment of cystic fibrosis
|
WO2007136635A1
(en)
|
2006-05-16 |
2007-11-29 |
Musc Foundation For Research Development |
Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators
|
WO2007146229A2
(en)
|
2006-06-07 |
2007-12-21 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
WO2007149328A1
(en)
|
2006-06-20 |
2007-12-27 |
Genzyme Corporation |
Serum-free media and their uses for chondrocyte expansion
|
WO2008003320A2
(en)
|
2006-07-05 |
2008-01-10 |
Region Midtjylland |
Three-dimensional cell scaffolds
|
AU2008204982A1
(en)
|
2007-01-05 |
2008-07-17 |
Mount Sinai School Of Medicine |
Acid ceramidase and cell survival
|
EP2442104A3
(en)
|
2007-04-06 |
2012-04-25 |
Genzyme Corporation |
Methods of evaluating cells and cell cultures
|
US8956825B2
(en)
|
2007-05-24 |
2015-02-17 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Intranuclear protein transduction through a nucleoside salvage pathway
|
NZ599928A
(en)
|
2007-05-31 |
2012-08-31 |
Glycan Biosciences |
Use of pentosan polysulfate for treatment or prophylaxis of asthma
|
FR2924946B1
(fr)
|
2007-12-18 |
2010-02-26 |
Oreal |
Utilisation cosmetique de proteines de type ceramidase acide
|
DE102007063535A1
(de)
|
2007-12-21 |
2009-06-25 |
Cycnad Gmbh & Co. Kg |
Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose
|
PL2659904T3
(pl)
|
2008-06-26 |
2016-01-29 |
Orphazyme Aps |
Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej
|
US20100068302A1
(en)
|
2008-09-17 |
2010-03-18 |
Traslational Cancer Drugs Pharma, S.L. |
Methods and compositions for the treatment of cancer
|
AU2009313400A1
(en)
|
2008-11-06 |
2010-05-14 |
Musc Foundation For Research Development |
Lysosomotropic inhibitors of acid ceramidase
|
WO2010127355A1
(en)
|
2009-05-01 |
2010-11-04 |
Mount Sinai School Of Medicine |
Method to determine embryo and oocyte quality based on ceramidase
|
PT3482767T
(pt)
|
2009-08-28 |
2021-12-29 |
Icahn School Med Mount Sinai |
Terapia de substituição enzimática com escaladas de dose para tratamento de deficência da esfingomielinase ácida
|
PL2995306T4
(pl)
|
2009-10-19 |
2019-07-31 |
Amicus Therapeutics, Inc. |
Nowe kompozycje do zapobiegania i/lub leczenia lizosomalnych zaburzeń spichrzeniowych
|
KR20200013105A
(ko)
|
2009-11-27 |
2020-02-05 |
젠자임 코포레이션 |
글루코실세라마이드 신타아제의 억제제로서 genz 112638 헤미타르타르산염의 무정형 및 결정질 형태
|
WO2012051415A2
(en)
|
2010-10-13 |
2012-04-19 |
Mount Sinai School Of Medicine |
Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
|
WO2013101276A2
(en)
|
2011-04-01 |
2013-07-04 |
Mount Sinai School Of Medicine |
Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway
|
WO2012154794A2
(en)
|
2011-05-10 |
2012-11-15 |
Advanced Liquid Logic, Inc. |
Enzyme concentration and assays
|
EP2721151B1
(en)
|
2011-06-20 |
2017-12-06 |
Mount Sinai School Of Medicine |
Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
|
SI2753346T1
(sl)
|
2011-09-07 |
2020-09-30 |
Mount Sinai School Of Medicine |
Ceramidaza in diferenciacija celic
|
ES2897825T3
(es)
|
2012-06-01 |
2022-03-02 |
Icahn School Med Mount Sinai |
Niveles de ceramida en el tratamiento y prevención de infecciones
|
PT2968479T
(pt)
|
2013-03-14 |
2019-08-07 |
Icahn School Med Mount Sinai |
Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
|